S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:BNTC

Benitec Biopharma (BNTC) Stock Price, News & Analysis

$5.14
+0.04 (+0.78%)
(As of 03/18/2024 ET)
Today's Range
$5.08
$5.18
50-Day Range
$2.80
$5.62
52-Week Range
$1.86
$9.01
Volume
2,271 shs
Average Volume
15,601 shs
Market Capitalization
$13.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Benitec Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.6% Upside
$10.00 Price Target
Short Interest
Healthy
0.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Benitec Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.35 out of 5 stars

Medical Sector

777th out of 947 stocks

Pharmaceutical Preparations Industry

365th out of 435 stocks

BNTC stock logo

About Benitec Biopharma Stock (NASDAQ:BNTC)

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

BNTC Stock Price History

BNTC Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Benitec Biopharma Inc BNTC
8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)
THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here:
JMP Securities Sticks to Its Buy Rating for Benitec Biopharma (BNTC)
Benitec Biopharma Inc.
Benitec Biopharma Shares Double on FDA Clearance
See More Headlines
Receive BNTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/18/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTC
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+94.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-19,560,000.00
Pretax Margin
-35,754.10%

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.12 per share

Miscellaneous

Free Float
2,481,000
Market Cap
$13.31 million
Optionable
No Data
Beta
1.02
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Jerel A. Banks M.D. (Age 49)
    Ph.D., Executive Chairman & CEO
    Comp: $848.07k
  • Ms. Megan Joan Boston BComm (Age 52)
    CA, Dip., GAICD, Executive Director
    Comp: $439.17k
  • Dr. Michael Graham
    Head of Discovery & Founding Scientist
  • Dr. Claudia Kloth
    Senior Vice President of Manufacturing

BNTC Stock Analysis - Frequently Asked Questions

Should I buy or sell Benitec Biopharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNTC shares.
View BNTC analyst ratings
or view top-rated stocks.

What is Benitec Biopharma's stock price target for 2024?

1 brokers have issued 12 month price targets for Benitec Biopharma's stock. Their BNTC share price targets range from $10.00 to $10.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 94.6% from the stock's current price.
View analysts price targets for BNTC
or view top-rated stocks among Wall Street analysts.

How have BNTC shares performed in 2024?

Benitec Biopharma's stock was trading at $3.23 on January 1st, 2024. Since then, BNTC stock has increased by 59.1% and is now trading at $5.14.
View the best growth stocks for 2024 here
.

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a increase in short interest in February. As of February 29th, there was short interest totaling 16,100 shares, an increase of 151.6% from the February 14th total of 6,400 shares. Based on an average daily trading volume, of 14,100 shares, the short-interest ratio is currently 1.1 days. Currently, 0.7% of the shares of the stock are sold short.
View Benitec Biopharma's Short Interest
.

When is Benitec Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our BNTC earnings forecast
.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) posted its earnings results on Tuesday, February, 13th. The biotechnology company reported ($2.64) earnings per share (EPS) for the quarter.

When did Benitec Biopharma's stock split?

Benitec Biopharma's stock reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager.

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.64%), Vanguard Group Inc. (0.65%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Benitec Biopharma?

Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNTC) was last updated on 3/18/2024 by MarketBeat.com Staff

From Our Partners